skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Patient Navigator Programs, Cancer Disparities, and the Patient Protection and Affordable Care Act

Moy, Beverly ; Chabner, Bruce A.

The oncologist (Dayton, Ohio), 2011-07, Vol.16 (7), p.926-929 [Periódico revisado por pares]

Durham, NC, USA: AlphaMed Press

Texto completo disponível

Citações Citado por
  • Título:
    Patient Navigator Programs, Cancer Disparities, and the Patient Protection and Affordable Care Act
  • Autor: Moy, Beverly ; Chabner, Bruce A.
  • Assuntos: Delivery of Health Care - economics ; Delivery of Health Care - legislation & jurisprudence ; Disparities in Cancer Care ; Health care law ; Health Services Accessibility - economics ; Health Services Accessibility - legislation & jurisprudence ; Healthcare Disparities - economics ; Healthcare Disparities - legislation & jurisprudence ; Humans ; Neoplasms - economics ; Neoplasms - ethnology ; Neoplasms - mortality ; Neoplasms - therapy ; Patient navigator programs ; Patient Protection and Affordable Care Act ; United States - epidemiology
  • É parte de: The oncologist (Dayton, Ohio), 2011-07, Vol.16 (7), p.926-929
  • Notas: Bruce A. Chabner
    Sanofi, Allergan, Epizyme, PharmaMar, GlaxoSmithKline, Peregrine, Onyx
    Research funding/contracted research
    Eli Lilly
    U.S. Government
    Avon Foundation
    Ownership interest
    Disclosures: Beverly Moy
    Consultant/advisory role
    Honoraria
    PharmaMar, Gilead, Epizyme, Human Genome Sciences, Onyx.
    The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Disclosures: Beverly Moy: Research funding/contracted research: Avon Foundation; Bruce A. Chabner: Consultant/advisory role: Sanofi, Allergan, Epizyme, PharmaMar, GlaxoSmithKline, Peregrine, Onyx; Honoraria: Eli Lilly; Research funding/contracted research: U.S. Government; Ownership interest: PharmaMar, Gilead, Epizyme, Human Genome Sciences, Onyx.
  • Descrição: Patients in vulnerable population groups suffer disproportionately from cancer. The elimination of cancer disparities is critically important for lessening the burden of cancer. Patient navigator programs have been shown to improve clinical outcomes. Among its provisions relevant to disparities in cancer care, The Patient Protection and Affordability Care Act authorizes continued funding of patient navigator programs. However, given the current economic and political environment, this funding is in jeopardy. This article describes patient navigator programs and summarizes the elements of the health care law that are relevant to these programs. It is vital that the entire oncology community remain committed to leading efforts toward the improvement of cancer care among our most vulnerable patients. 摘要 罹患癌症的弱势群体患者所遭受痛苦的强烈程度非常之大。消除癌症治疗差距在减轻癌症负担中起到至关重要的作用。现已证明患者导航项目能够改善临床结果。在与癌症治疗差距相关的规定中，患者保护与平价医疗法批准继续资助患者导航项目。然而，考虑到当前的经济与政治环境，这种资助已陷入危险境地。本文介绍了患者导航项目并总结了医疗保健法中与这些项目相关的规定。重要的是，在力图改善大多数弱势患者的癌症治疗方面，整个肿瘤学界仍身负领导者的使命。 The article describes patient navigator programs and summarizes the elements of the health care law that are relevant to these programs.
  • Editor: Durham, NC, USA: AlphaMed Press
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.